Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo

Identification of host factors contributing to replication of viruses and resulting disease progression remains a promising approach for development of new therapeutics. Here, we evaluated 6710 clinical and preclinical compounds targeting 2183 host proteins by immunocytofluorescence-based screening...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Patten, J.J., Keiser, Patrick T., Gysi, Deisy, Menichetti, Giulia, Mori, Hiroyuki, Donahue, Callie J., Gan, Xiao, do Valle, Italo, Geoghegan-Barek, Kathleen, Anantpadma, Manu, Boytz, RuthMabel, Berrigan, Jacob L., Hulsey-Stubbs, Sarah, Ayazika, Tess, O’Leary, Colin, Jalloh, Sallieu, Wagner, Florence, Ayehunie, Seyoum, Elledge, Stephen J., Anderson, Deborah, Loscalzo, Joseph, Zitnik, Marinka, Gummuluru, Suryaram, Namchuk, Mark N., Barabási, Albert-László, Davey, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2022
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077576/
https://ncbi.nlm.nih.gov/pubmed/33907750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.20.440626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados